| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Medical and professional news |
| Population | Men |
| Source | Targeted Oncology |
| URL | targetedonc.com/view/sexual-physical-function-after-prostatectomy-improved-by-trt (opens in a new tab) |
Specific Claim Evaluated
Testosterone cypionate 100 mg weekly for 12 weeks increased sexual activity by 0.91 daily events over placebo in men with hypogonadism after prostatectomy for low-grade cancer, with no biochemical recurrence and erythrocytosis only in the testosterone group.
Primary Research Supporting or Contradicting the Claim
The SPIRIT trial reported a between-group difference in sexual activity of 0.91 daily events, no biochemical recurrence, no change in erectile function and a duration insufficient to assess clinical recurrence (Bhasin et al., 2026).
Corrected Evidence-Based Interpretation
The report is correct.
Rationale for Grade
The article reports the effect size, the null erectile function result, the adverse events and the single-site limitation for physical performance testing. All figures match the published trial.
References
- Bhasin S, Burnett AL, Gagliano-Jucá T, Storer TW, Reid KF, Shang YV, Privat F, Chandra MS, Weiss M, Memish-Beleva Y, Lam H, Kibel AS, Pencina KM. Testosterone treatment in prostate cancer survivors with hypogonadism: a randomized clinical trial. JAMA Intern Med. 2026;186(7):805-814. PMID
Supporting excerpt: "The trial was neither long enough nor large enough to evaluate clinical recurrence"